Here are the 10-K annual reports from RetinalGenix Technologies (RTGN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RTGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RTGN filings page.
RetinalGenix Technologies Inc. files its annual report describing a development-stage ophthalmic business with no product revenue and recurring net losses. The company focuses on four pillars: genetic testing, retinal imaging, a patient information database, and repurposed pharmaceutical therapies for dry age-related macular degeneration and Alzheimer’s dementia.
Management plans initial genetic test sales and beta retinal imaging in 2026 and potential commercialization in 2027, but discloses substantial doubt about its ability to continue as a going concern. RetinalGenix estimates it needs about $7 million in additional funding and has recently raised smaller amounts through private stock placements.